---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012879"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:06:41.769203+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses

## Summary
- New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.
- Acclaim-1 Phase 2a enrolling; Phase 1 showed no DLTs, one patient had partial remission for ~42 months (60 courses) on Reqorsa+Tagrisso.
- Acclaim-3 Phase 2 enrolling; Phase 1 showed no DLTs, one patient had unconfirmed partial remission after 24 cycles (>18 months) on Reqorsa+Tecentriq.
- Both trials combine Reqorsa (quaratusugene ozeplasmid) with approved targeted therapies; early signs of efficacy reported.

## SEC filing metadata
- accession: 0001437749-26-012879
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926012879/0001437749-26-012879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926012879/gnpx20260329_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012879
- JSON: https://secwatch.observer/filing/0001437749-26-012879.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.